Clinical trials: Chronic Infection
Hepatitis B
A Study of GSK3228836 in Participants With Chronic Hepatitis B (CHB)
Chronic hepatitis B virus (HBV) infection is a significant worldwide medical problem. GSK3228836 demonstrated target engagement in CHB participants who were not on treatment and in CHB participants on stable nucleos(t)ide…
- Trial name
- B-Clear (NCT04449029)
- Testing
- GSK3228836, Nucleos(t)ide therapy
- Where
- 121 sites in United States, Argentina and 20 more
- Volunteers
- 457 people
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis C
Peginterferon Alfa-2a and Ribavirin for Genotype 2 Chronic Hepatitis C: Duration and Ribavirin Dose Stratified by RVR
Treatment with peginterferon plus daily low dose (800 mg) or weight-based ribavirin (800-1400 mg) for 24 to 48 weeks has achieved 70-93% sustained virologic response (SVR) rates in patients with genotype 2 or 3 chronic hepatitis…
- Trial name
- NCT00532701
- Testing
- Peg-IFN + WB RBV for 16 weeks, Peg-IFN + LD RBV for 16 weeks, Peg-IFN + WB RBV for 24 weeks
- Where
- 9 sites in Taiwan
- Volunteers
- 880 people
- Sponsor
- National Taiwan University Hospital
Chronic Kidney Disease Requiring Chronic Dialysis
Activation of the Contact System and the Immune System in Patients With Chronic Kidney Disease.
Patients with end-stage renal disease undergoing hemodialysis (HD) are burdened with extremely high mortality rates (15% per year) and during the early stage (≤120days) the mortality rate is even higher (27% per year).
- Trial name
- AKIM-CKD (NCT05266092)
- Testing
- Observational study
- Where
- Denmark
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Odense University Hospital
Atopic Dermatitis, Psoriasis
Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases
Chronic inflammatory skin diseases constitute a heterogeneous group of pathologies. They affect the skin but also other organs (joints, lungs, muscles, etc.). Their prognosis and response to treatments is extremely variable.
- Conditions
- Atopic Dermatitis, Psoriasis, Hidradenitis Suppurativa, Lichen Planus
- Trial name
- ImmuneSkinBank (NCT06599411)
- Testing
- Sampling
- Where
- France
- Volunteers
- 830 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatitis C, Medication Adherence
Directly Observed Hepatitis C Treatment in Methadone Clinics
Drug users account for a disproportionately large burden of hepatitis C virus (HCV) infection. However, HCV treatment adherence rates in drug users may be suboptimal in patients who use drugs regularly during HCV treatment.
- Trial name
- NCT01442311
- Testing
- enhanced DOT (both pegylated interferon alfa-2a and ribavirin), standard DOT (PEG-DOT control arm)
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Albert Einstein College of Medicine
COVID-19, Long COVID-19
Effects of Physiotherapy Via Telerehabilitation in Patients With COVID-19
This study aims to evaluate the effects of Physiotherapy Via Video Calls on Cardiopulmonary Functions, Physical Function, Cognitive Function, Activity Daily Livings, and Quality of Life in Patients With COVID-19.
- Conditions
- COVID-19, Long COVID-19, Cardiopulmonary Function, Physical Function
- Trial name
- NCT06251011
- Testing
- Exercise training
- Where
- Thailand
- Volunteers
- 32 people
- Sponsor
- Chulabhorn Hospital
Hepatitis B, Chronic Hepatitis B
Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in Healthy Volunteers
This is an open-label, randomized, multi-part study to evaluate the relative oral bioavailability of a tablet formulation of AL-3778 (formerly NVR 3-778) administered under fasted and fed conditions (Parts 1 and 2) and the…
- Conditions
- Hepatitis B, Chronic Hepatitis B, Viral Hepatitis B
- Trial name
- NCT03032536
- Testing
- AL-3778, Entecavir, Tenofovir disoproxil fumarate
- Where
- 2 sites in New Zealand
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Alios Biopharma Inc.
Chronic Hepatitis C
Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care
The purpose of the study is to determine whether therapy with the combination of PSI-7977 and daclatasvir (BMS-790052) with or without ribavirin is effective in treating hepatitis C virus (HCV) infection when given for 12 or 24…
- Trial name
- NCT01359644
- Testing
- PSI-7977, Daclatasvir, Ribavirin
- Where
- 18 sites in United States, Puerto Rico
- Volunteers
- 350 people
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis B
Switch or Sequential Combination Therapy of Peginterferon in Hepatitis B Patients With Longterm Entecavir Therapy
This is a multicenter, prospective cohort study to evaluate the efficacy and safety of sequential combination or switch therapy of pegylated interferon alfa-2a in chronic hepatitis B patients with low HBsAg and HBeAg titers after…
- Trial name
- NCT02589652
- Testing
- Pegylated interferon alfa-2a, Pegylated interferon alfa-2a plus Entecavir, Entecavir
- Where
- 17 sites in China
- Volunteers
- 294 people
- Sponsor
- Huashan Hospital
COVID-19
Impact of Long COVID-19 on the Health and Quality of Life of Military Personnel (Active or Retired) and Their Families
Severe and sometimes irreversible sequelae are observed in people who have developed a severe form of COVID-19 (pulmonary, cardiovascular, renal, neurological sequelae among others).
- Trial name
- IMP@LA (NCT05200832)
- Testing
- Online questionnaire, Semi-structured interview
- Where
- France
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Direction Centrale du Service de Santé des Armées
Hepatitis C Virus Infection, Hepatitis C Virus Infection, Response to Therapy of
HCV Reinfection in HD Patients Achieving SVR
Among the hemodialysis units, the global incidence of HCV infection ranges from 1.2% to 2.9%. Data regarding the long-term risk of reinfection among hemodialysis patients achieving SVR are limited.
- Conditions
- Hepatitis C Virus Infection, Hepatitis C Virus Infection, Response to Therapy of, Hemodialysis Complication
- Trial name
- NCT04732832
- Where
- 7 sites in Taiwan
- Volunteers
- 350 people
- Sponsor
- National Taiwan University Hospital
Pulmonary Disease, Influenza
An RCT of Oseltamivir in Outpatients With CPD: A Pilot Study.
The proposed pilot study will provide needed data to establish the feasibility of a conducting a large randomized controlled trial as to the effectiveness of the use of oseltamivir early in the course of influenza in outpatients…
- Trial name
- AVT (NCT02282384)
- Testing
- oseltamivir
- Sponsor
- McMaster University
Chronic Illness
Intradermal Trivalent Influenza Vaccine With Imiquimod
Despite the WHO International Health Regulations Emergency Committee declared an end to the 2009 H1N1 pandemic globally, the emergence of the novel 2009 H1N1 virus in March 2009 has affected more than 214 countries with at least…
- Trial name
- NCT01508884
- Testing
- influenza vaccine, Imiquimod, Aqueous cream
- Where
- Hong Kong
- Volunteers
- 93 people
- Sponsor
- The University of Hong Kong
COPD (Chronic Obstructive Pulmonary Disease), Rhinovirus Infection
Using Multiomics to Define Mechanisms of Rhinovirus-induced Chronic Obstructive Pulmonary Disease Exacerbations to Develop Novel Therapies and Therapeutic Targets
The goal of this study is to examine exacerbations of chronic obstructive pulmonary disease (COPD) caused by a common cold virus called rhinovirus, to identify new treatments.
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease), Rhinovirus Infection, Exacerbation of COPD
- Trial name
- MRVCOPD (NCT07112235)
- Testing
- Rhinovirus-A16
- Where
- United Kingdom
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Sinusitis
Xolair in Patients With Chronic Sinusitis
The purpose of this study is to determine if treatment with the anti-IgE antibody, Xolair (omalizumab), will improve objective and subjective evidence of chronic sinusitis.
- Trial name
- NCT00117611
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Chicago
Hepatitis C
Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients
The purpose of this study is to follow-up with participants from feeder studies who achieved sustained virologic response (SVR) over 24 hours posttreatment (SVR24), to assess durability of SVR, and to assess the changes in liver…
- Trial name
- NCT02753699
- Testing
- Alisporivir
- Where
- 119 sites in United States, Argentina and 20 more
- Volunteers
- 723 people
- Sponsor
- Debiopharm International SA
Chronic Hepatitis B
Evaluation of cccDNA and Total HBV DNA Kinetics in Lymphocytes, Total Blood and Serum in Chronic Hepatitis B Patients Treated With Adefovir Dipivoxil and Peg Interferon Alpha 2a
Serum HBV DNA is a referent but insufficient marker of therapeutic follow-up in chronic hepatitis B treatment. Intra hepatic cccDNA disappearance reflects HBV eradication in the liver.
- Trial name
- DNA-EVAL (NCT00199732)
- Where
- 4 sites in France
- Volunteers
- 19 people
- Sponsor
- University Hospital, Limoges
Hypogammaglobulinemia
Cytomegalovirus Hyperimmune Globulin (CMV-Ig) Replacement in Hypogammaglobulinemic Lung Transplant Recipients
This is a randomized controlled trial of CMV-Ig in lung transplant recipients at the Cleveland Clinic Foundation who are hypogammaglobulinemic.
- Trial name
- NCT00137748
- Testing
- CMV-Ig
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- The Cleveland Clinic
Hepatitis, Chronic Active
CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects
The purpose of this study is to determine the efficacy and tolerability of CPG 10101 at two different dose levels with pegylated-interferon-alpha 2B (PEG-IFN) plus ribavirin (RBV) compared to PEG-IFN and RBV without CPG 10101 in…
- Trial name
- NCT00277238
- Testing
- CPG10101, Control
- Where
- 14 sites in United States
- Volunteers
- 113 people
- Sponsor
- Pfizer
Chronic Hepatitis C
Study of the Efficacy and Safety of Pegnano Plus Barivir (Ribavirin) in Treatment-naïve Patients With Chronic Hepatitis C at KienGiang General Hospital
This study presents a clinical study on the efficacy and safety of Pegnano combined with Barivir (Ribavirin) in treating treatment-naïve patients with Chronic Hepatitis C at Kien Giang General Hospital.
- Trial name
- NCT06922643
- Testing
- Peginterferon Alfa-2A, Ribavirin Oral Product
- Volunteers
- 100 people
- Sponsor
- Nanogen Pharmaceutical Biotechnology Joint Stock Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.